Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 4 (April)

1. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
   Breast Cancer Res Treat, 90(2): 157-63. [Abstract] [Full-text]
2. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
   Blood, 105(8): 3127-32. [Abstract] [Full-text]
3. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
   Blood, 105(8): 3303-11. [Abstract] [Full-text]
4. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.
   Blood, 105(8): 3319-21. [Abstract] [Full-text]
5. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
   Blood, 105(8): 3270-7. [Abstract] [Full-text]
6. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
   Cancer Res, 65(7): 2914-20. [Abstract] [Full-text]
7. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
   Cancer Res, 65(7): 2676-83. [Abstract] [Full-text]
8. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
   Cancer Res, 65(7): 2577-82. [Abstract] [Full-text]
9. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument.
   Value Health, 8(2): 117-27. [Abstract] [Full-text]
10. Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB.
    J Biol Chem, 280(14): 13936-43. [Abstract] [Full-text]
11. Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.
    Am J Ophthalmol, 139(4): 723-4. [Abstract] [Full-text]
12. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Curr Med Res Opin, 21(3): 403-11. [Abstract] [Full-text]
13. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
    Int J Hematol, 81(3): 242-5. [Abstract] [Full-text]
14. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
    Int J Hematol, 81(3): 235-41. [Abstract] [Full-text]
15. Post-inflammatory glomerular remodeling is influenced by transformed mesangial cells.
    Pathol Int, 55(4): 189-201. [Abstract] [Full-text]
16. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Cancer, 103(8): 1659-69. [Abstract] [Full-text]
17. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.
    Am J Physiol Gastrointest Liver Physiol, 288(5): G907-13. [Abstract] [Full-text]
18. Fast apoptosis and erythroid differentiation induced by imatinib mesylate in JURL-MK1 cells.
    J Cell Biochem, 95(2): 268-80. [Abstract] [Full-text]
19. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
    Chem Biol Interact, 152(2): 139-50. [Abstract] [Full-text]
20. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Pharmacotherapy, 25(3): 325-34. [Abstract] [Full-text]
21. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients.
    Histopathology, 46(5): 540-50. [Abstract] [Full-text]
22. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Blood, 105(9): 3449-57. [Abstract] [Full-text]
23. Lack of clinical efficacy of imatinib in metastatic melanoma.
    Br J Cancer, 92(8): 1398-405. [Abstract] [Full-text]
24. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
    Cancer, 103(9): 1850-5. [Abstract] [Full-text]
25. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Cancer, 103(9): 1800-9. [Abstract] [Full-text]
26. Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib.
    Exp Hematol, 33(5): 542-9. [Abstract] [Full-text]
27. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
    Leukemia, 19(5): 792-8. [Abstract] [Full-text]
28. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
    Leukemia, 19(4): 507-12. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.